MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- VENUS REMEDIES - ADCOCK INGRAM (S. Africa)
VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 VENUS REMEDIES  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-18 |
ADCOCK INGRAM Jun-14 |
VENUS REMEDIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 352 | - | |
| Low | Rs | 61 | 254 | - | |
| Sales per share (Unadj.) | Rs | 301.8 | 104.8 | - | |
| Earnings per share (Unadj.) | Rs | -24.9 | -26.4 | - | |
| Cash flow per share (Unadj.) | Rs | 2.5 | -21.9 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 293.3 | 82.3 | - | |
| Shares outstanding (eoy) | m | 12.34 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 2.9 | 10.7% | |
| Avg P/E ratio | x | -3.8 | -11.5 | 32.7% | |
| P/CF ratio (eoy) | x | 36.7 | -13.9 | -265.2% | |
| Price / Book Value ratio | x | 0.3 | 3.7 | 8.6% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,154 | 51,185 | 2.3% | |
| No. of employees | `000 | 0.9 | 4.3 | 21.5% | |
| Total wages/salary | Rs m | 393 | 3,212 | 12.2% | |
| Avg. sales/employee | Rs Th | 4,026.1 | 4,120.8 | 97.7% | |
| Avg. wages/employee | Rs Th | 425.0 | 748.3 | 56.8% | |
| Avg. net profit/employee | Rs Th | -331.8 | -1,038.3 | 32.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 3,724 | 17,690 | 21.1% | |
| Other income | Rs m | 23 | 124 | 18.2% | |
| Total revenues | Rs m | 3,747 | 17,814 | 21.0% | |
| Gross profit | Rs m | 395 | -3,066 | -12.9% | |
| Depreciation | Rs m | 338 | 764 | 44.3% | |
| Interest | Rs m | 354 | 479 | 73.9% | |
| Profit before tax | Rs m | -275 | -4,184 | 6.6% | |
| Minority Interest | Rs m | 0 | -12 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 32 | 261 | 12.1% | |
| Profit after tax | Rs m | -307 | -4,458 | 6.9% | |
| Gross profit margin | % | 10.6 | -17.3 | -61.2% | |
| Effective tax rate | % | -11.5 | -6.2 | 183.7% | |
| Net profit margin | % | -8.2 | -25.2 | 32.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,638 | 12,957 | 20.4% | |
| Current liabilities | Rs m | 2,305 | 7,290 | 31.6% | |
| Net working cap to sales | % | 8.9 | 32.0 | 27.9% | |
| Current ratio | x | 1.1 | 1.8 | 64.4% | |
| Inventory Days | Days | 135 | 111 | 122.1% | |
| Debtors Days | Days | 46 | 124 | 37.4% | |
| Net fixed assets | Rs m | 4,871 | 7,552 | 64.5% | |
| Share capital | Rs m | 123 | 82 | 150.2% | |
| Net worth | Rs m | 3,619 | 13,885 | 26.1% | |
| Long term debt | Rs m | 1,374 | 4,879 | 28.2% | |
| Total assets | Rs m | 7,509 | 26,230 | 28.6% | |
| Interest coverage | x | 0.2 | -7.7 | -2.9% | |
| Debt to equity ratio | x | 0.4 | 0.4 | 108.1% | |
| Sales to assets ratio | x | 0.5 | 0.7 | 73.5% | |
| Return on assets | % | 0.6 | -15.2 | -4.2% | |
| Return on equity | % | -8.5 | -32.1 | 26.4% | |
| Return on capital | % | 1.6 | -19.8 | -8.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 514 | 1,510 | 34.1% | |
| From Investments | Rs m | -123 | -464 | 26.6% | |
| From Financial Activity | Rs m | -387 | 4,428 | -8.7% | |
| Net Cashflow | Rs m | 4 | 5,475 | 0.1% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.86 Rs / ZAR
Compare VENUS REMEDIES With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare VENUS REMEDIES With: DISHMAN PHARMA ALKEM LABORATORIES TORRENT PHARMA BIOCON GLENMARK PHARMA
Today's Market
Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
Related Views On News
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More
